These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 19185649)

  • 1. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
    Finn AV; Oh JS; Hendricks M; Daher M; Cagliero E; Byrne RM; Nadelson J; Crimins J; Kastrati A; Schömig A; Bruskina O; Palacios I; John MC; Gold HK
    Am Heart J; 2009 Feb; 157(2):383.e1-8. PubMed ID: 19185649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience.
    Fang CC; Ng Jao YT; Yi-Chen ; Yu CL; Chen CL; Wang SP
    Angiology; 2007; 58(5):523-34. PubMed ID: 18024934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
    Choi D; Kim SK; Choi SH; Ko YG; Ahn CW; Jang Y; Lim SK; Lee HC; Cha BS
    Diabetes Care; 2004 Nov; 27(11):2654-60. PubMed ID: 15505001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
    García-García HM; Garg S; Brugaletta S; Morocutti G; Ratner RE; Kolatkar NS; Kravitz BG; Miller DM; Huang C; Nesto RW; Serruys PW;
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):455-65. PubMed ID: 21359834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
    Hausleiter J; Kastrati A; Mehilli J; Vogeser M; Zohlnhöfer D; Schühlen H; Goos C; Pache J; Dotzer F; Pogatsa-Murray G; Dirschinger J; Heemann U; Schömig A;
    Circulation; 2004 Aug; 110(7):790-5. PubMed ID: 15302787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bare metal stent with pioglitazone versus sirolimus-eluting stent for percutaneous coronary intervention in patients with Type 2 diabetes mellitus.
    Nishio K; Shigemitsu M; Kodama Y; Konno N; Katagiri T; Kobayashi Y
    Cardiovasc Revasc Med; 2009; 10(1):5-11. PubMed ID: 19159848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
    Osman A; Otero J; Brizolara A; Waxman S; Stouffer G; Fitzgerald P; Uretsky BF
    Am Heart J; 2004 May; 147(5):e23. PubMed ID: 15131558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of C-reactive protein and interleukin-10 predict late coronary in-stent restenosis 6 months after elective stenting.
    Zurakowski A; Wojakowski W; Dzielski T; Milewski K; Gościńska-Bis K; Tendera M; Buszman P
    Kardiol Pol; 2009 Jun; 67(6):623-30. PubMed ID: 19618318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial.
    Chaves AJ; Sousa AG; Mattos LA; Abizaid A; Staico R; Feres F; Centemero M; Tanajura LF; Abizaid A; Pinto I; Maldonado G; Seixas A; Costa MA; Paes A; Mintz GS; Sousa JE
    Circulation; 2004 Feb; 109(7):861-6. PubMed ID: 14757690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial.
    Sabaté M; Jiménez-Quevedo P; Angiolillo DJ; Gómez-Hospital JA; Alfonso F; Hernández-Antolín R; Goicolea J; Bañuelos C; Escaned J; Moreno R; Fernández C; Fernández-Avilés F; Macaya C;
    Circulation; 2005 Oct; 112(14):2175-83. PubMed ID: 16203930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries.
    Popma JJ; Leon MB; Moses JW; Holmes DR; Cox N; Fitzpatrick M; Douglas J; Lambert C; Mooney M; Yakubov S; Kuntz RE;
    Circulation; 2004 Dec; 110(25):3773-80. PubMed ID: 15596568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials.
    Rosmarakis ES; Falagas ME
    Am Heart J; 2007 Jul; 154(1):144-50. PubMed ID: 17584567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latin American randomized trial of balloon angioplasty versus coronary stenting in diabetic patients with small vessel reference size (Latin American Small Vessel [LASMAL II] Trial): immediate and long-term results.
    Rodriguez AE; Rodriguez Alemparte M; Fernandez Pereira C; Vigo CF; Sampaolesi A; Bernardi V; Marchand E; Tronge J; Palacios IF;
    Am Heart J; 2005 Jul; 150(1):188. PubMed ID: 16086559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-interventional homocysteine levels: failure as a predictive biomarker of in-stent restenosis.
    Breuckmann F; Naber C; Beckert J; Schmermund A; Haude M; Baumgart D; Erbel R
    Int J Cardiol; 2006 Mar; 108(1):20-5. PubMed ID: 16516694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized blinded clinical trial of intracoronary brachytherapy with 90Sr/Y beta-radiation for the prevention of restenosis after stent implantation in native coronary arteries in diabetic patients.
    Syeda B; Schukro C; Kirisits C; Lang I; Siostrzonek P; Gottsauner-Wolf M; Pokrajac B; Schmid R; Yahya N; Pötter R; Glogar D
    Radiother Oncol; 2006 Jan; 78(1):60-6. PubMed ID: 16309769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.